Publications by authors named "A Lazzarin"

The present study aims to investigate the relationship between cerebellar volumes and cognitive reserve in individuals with Mild Cognitive Impairment (MCI). A description of proxies of cerebellar cognitive reserve in terms of different volumes across lobules is also provided. 36 individuals with MCI underwent neuropsychological (MoCA, MMSE, Clock test, CRIq) assessment and neuroimaging acquisition with magnetic resonance imaging at 3 T.

View Article and Find Full Text PDF
Article Synopsis
  • - The study assessed the safety and effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after 144 weeks of dolutegravir (DTG)-based therapy in HIV-1 patients.
  • - After 96 weeks on B/F/TAF, over 99% of participants maintained viral suppression and had stable CD4+ cell counts without emerging resistance, though some experienced mild side effects like diarrhea and weight gain.
  • - The findings support the switch to B/F/TAF as a safe and effective long-term treatment option for people previously on DTG-containing regimens.
View Article and Find Full Text PDF

Background: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the metastatic renal cell carcinoma (mRCC) therapeutic landscape. Nevertheless, tyrosine-kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) axis still play a key role. The aim of the present study was to explore the prognostic performance of an integrated blood score, based on hemoglobin (Hb) concentration, mean corpuscular volume (MCV), and red cell distribution width (RDW), in mRCC patients treated with anti-VEGF TKIs.

View Article and Find Full Text PDF

The aim of the TWODAY Study was to investigate the frequency of early treatment change after rapid start of a tailored ART regimen (a 2-drug regimen - 2DR, when clinically feasible or a 3-drug regimen - 3DR, otherwise). TWODAY was an open-label, prospective, proof-of-concept, single center study. ART-naïve patients started their first-line regimen within a few days from the first laboratory testing with a 2DR of dolutegravir (DTG) and lamivudine (3TC) if CD4+ count >200 cells/mL, HIVRNA <500,000 copies/mL, no transmitted drug resistance to DTG or 3TC and HBsAg undetectable; otherwise, ART was started with a 3DR.

View Article and Find Full Text PDF